Product Program year 2019 Source: CMS Open Payments

Bivv020

Drug

Open in the dashboard

General payments

$8,886

11 payments

Research payments

0 payments

Through program year 2019, $8,886 in general payments and $0 in research payments were reported against Bivv020.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row

Year	Kind	Amount	Payments
2019	General	$8,886	11

Breakdown

Who paid General payments · program year 2019

Sanofi US Services Inc. $8,886 11 payments

Top recipients General payments · program year 2019

Andrew Williams Internal Medicine · Pasadena, CA $3,911 44% · 5 payments
Walter Le Internal Medicine · Whittier, CA $1,838 21% · 3 payments
Joseph Dellinger Internal Medicine · Pasadena, CA $1,500 17% · 1 payment
Christopher Dagher Internal Medicine · Pasadena, CA $938 11% · 1 payment
Mireille Hamparian Ophthalmology · Glendale, CA $700 8% · 1 payment

Each share is of general payments naming this product in 2019.

Specialties paid General payments · program year 2019

Internal Medicine $8,186 92% · 4 practitioners
Ophthalmology $700 8% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2019

California $8,886 100% · 5 recipients

Each share is of general payments naming this product in 2019 where a state was reported.

Records

11 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.